Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Clinical trial NCT06160609 · TERMINATED

Trial details

NCT number: NCT06160609
Sponsor: GlaxoSmithKline
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Multiple Myeloma

Start date: 2019-10-07
Primary completion: 2023-01-09
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.